Healthcare entity

Menarini

Company

Every one of those 1 sits in a single category, market-trends. AstraZeneca is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 7 average consequence score is above the beat benchmark of 6 in the same window.

Last mentioned: Mar 9, 2026

Entity pulse

Recent coverage · Menarini

1 story
7 avg impact
0% positive
100% negative

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.

  • 100% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Menarini

Every one of those 1 sits in a single category, market-trends. AstraZeneca is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 7 average consequence score is above the beat benchmark of 6 in the same window. Each story carries 4 original sources on average, compared with 4.1 for the broader beat in this window. Menarini appears in 1 tracked Healthcare story from March 9, 2026.

Stories tracked
1
Sources per story
4

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Menarini. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Trial Failure Announced

    Roche confirms the oral SERD candidate failed to meet primary endpoints; shares dip immediately.

  2. Phase II Data Review

    Earlier data had suggested potential efficacy, leading to high investor expectations for the Phase III results.

  3. Combination Trials Launch

    Roche expanded the program to include combination therapies with CDK4/6 inhibitors.

Stories mentioning Menarini 1

Menarini is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.